分次立体定向放射外科治疗恶性胶质瘤:与单次立体定向放射外科的比较
回顾性分析2015年1月至2018年12月接受伽玛刀立体定向放射外科的58例恶性胶质瘤患者,41例接受单次SRS,17例接受分次SRS。两组中位无进展生存期分别为4.5和4.6个月(p=0.58),中位总生存期分别为12.7和12.6个月(p=0.41),临床显著放射性坏死发生率分别为20.5%(8/39)和18.8%(3/16)(p=1)。作者认为分次SRS的局部控制与生存与单次SRS相当,若考虑再照射大体积恶性胶质瘤,分次SRS可能是更好的替代选择。
要点
- 分次SRS中位剂量28 Gy(范围24-35 Gy),中位单次剂量6 Gy(范围5-7 Gy),连续4或5次照射。
- 单次SRS中位剂量18 Gy(范围11-25 Gy),中位等剂量线50%(范围50-65%)。
- 两组中位PFS 4.5 vs 4.6个月(p=0.58),中位OS 12.7 vs 12.6个月(p=0.41),无显著差异。
核心结论
- 分次SRS治疗恶性胶质瘤的局部控制与生存与常规单次SRS相当。
- 当分次SRS组对大体积靶区给予平行生物有效剂量时,两组放射性坏死发生率相当。
- 若考虑再照射大体积恶性胶质瘤,分次SRS可能是优于单次SRS的替代选择。
研究设计与样本
- 回顾性研究,纳入2015年1月至2018年12月接受伽玛刀SRS的恶性胶质瘤患者58例,其中单次SRS组41例,分次SRS组17例。
主要发现
- 分次SRS组中位剂量28 Gy(范围24-35 Gy),中位单次剂量6 Gy(范围5-7 Gy),连续4或5次照射;单次SRS组中位剂量18 Gy(范围11-25 Gy),中位等剂量线50%(范围50-65%)。
- 单次SRS组与分次SRS组平均靶体积分别为5.9 cc和19.3 cc(p<0.001,双侧t检验)。
- 单次SRS组与分次SRS组中位无进展生存期分别为4.5和4.6个月(p=0.58),中位总生存期分别为12.7和12.6个月(p=0.41)(log-rank检验)。
- 单次SRS组与分次SRS组临床显著放射性坏死发生率分别为20.5%(8/39)和18.8%(3/16)(p=1,Fisher精确检验)。
临床怎么用
- 作者认为,若考虑再照射大体积恶性胶质瘤,分次SRS可能是优于单次SRS的替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic radiosurgery (SRS) is feasible for malignant glioma; however, delivering the optimal radiation dose with sufficient large-volume coverage is a major concern. We aimed to investigate the clinical efficacy and safety of fractionated SRS (fSRS) versus single-session SRS (sSRS) for malignant gliomas. METHODS: We retrospectively reviewed 58 malignant glioma patients who underwent gamma knife SRS from January 2015 to December 2018. Forty-one underwent sSRS, and 17 underwent fSRS. Median dose for fSRS was 28 Gy (range 24-35 Gy), with a median dose of 6 Gy per fraction (range 5-7 Gy). Patients received 4 or 5 fractions on consecutive days. Median dose for sSRS was 18 Gy (range 11-25 Gy), with a median isodose of 50% (range 50-65%). Mean target volumes were 5.9 and 19.3 cc for sSRS and fSRS, respectively (p < 0.001, two-sided t test). RESULTS: After SRS, median progression-free survival (PFS) was 4.5 and 4.6 months (p = 0.58), and median overall survival (OS) was 12.7 and 12.6 months for sSRS and fSRS (p = 0.41), respectively (log-rank test). The incidence of clinically significant radiation necrosis was 20.5% (8/39) and 18.8% (3/16) for sSRS and fSRS, respectively (p = 1, Fisher's exact test). CONCLUSION: fSRS for malignant glioma conferred local control and survival comparable with conventional sSRS. The radiation necrosis incidence was comparable between groups when a parallel biological effective dose was administered to the larger target volumes in the fSRS group. fSRS can be a better alternative to sSRS if re-irradiation is considered for large malignant gliomas.
引用
- Choi SW, Cho KR, Choi JW, et al. Fractionated stereotactic radiosurgery for malignant gliomas: comparison with single session stereotactic radiosurgery. J Neurooncol. 2019. PMID: 31705245. doi:10.1007/s11060-019-03328-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。